This is the authors' abstract. We don't add key points for this paper.
Introduction The ongoing challenge of SARS-CoV-2 and its evolving variants highlights the need for new therapeutic strategies to address viral replication and the inflammatory complications associated with COVID-19.Aims This study aimed to investigate the biological effects of essential oils from Eucalyptus staigeriana, Eucalyptus exserta, Eucalyptus leptophleba and eucalyptol, against SARS-CoV-2 and COVID-19 complications.Methods Essential oils were extracted from leaves by steam distillation, while eucalyptol was commercially obtained. The chemical composition was analyzed using gas chromatography-mass spectrometry. In vitro experiments assessed the cytotoxicity and antiviral activity of essential oils and eucalyptol. Inflammatory cytokines were quantified by flow cytometry.Results The essential oils yielded 3.59% (E. staigeriana), 0.79% (E. exserta), and 0.32% (E. leptophleba). Common major constituents included α-pinene, (-)-β-pinene, o-cymene, D-limonene, eucalyptol, γ-terpinene, and terpinolene. Antiviral assays showed that none of the essential oils or eucalyptol inhibited SARS-CoV-2 at non-cytotoxic concentrations. However, significant modulation of pro-inflammatory cytokines was observed. E. staigeriana exhibited the most effective regulation of IL-6 levels. Additionally, both essential oils and eucalyptol controlled MCP-1 and CXCL10 levels. All treatments maintained low IL-8 levels, except for E. leptophleba.Conclusions These findings suggest that eucalyptus-derived compounds could offer therapeutic benefits in managing COVID-19-related inflammation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Furtado et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: